{
  "abstract": "To characterize anti-nucleocapsid (anti-N) IgG binding antibody responses following first PCR-confirmed SARS-CoV-2 infections in a highly vaccinated population, we evaluated antibody boosting and durability in a longitudinal cohort in Michigan. Among 113 participants with paired pre- and post-infection serum specimens tested using a multiplex electrochemiluminescence assay, SARS-CoV-2 infection induced substantial boosting of anti-N IgG concentrations; approximately 80% of participants becoming anti-N seropositive following infection, and 81% of participants demonstrating at least a 4-fold rise in antibody concentrations following infection. Population-level analyses of 66 participants with post-infection serum specimens collected 52-120 days after infection demonstrated sustained anti-N IgG concentrations over time, with no evidence of substantial decline. These findings demonstrate robust boosting and sustained infection-induced anti-N IgG responses in a highly vaccinated population through four months following SARS-CoV-2 infection. This supports the use of anti-N antibodies for longitudinal serosurveillance, including those who are vaccinated.",
  "abstract_shown": true,
  "affiliations": [
    "University of Michigan-Ann Arbor"
  ],
  "article_type": "PUBLISHAHEADOFPRINT",
  "arxiv": null,
  "author_total": 11,
  "authors": [
    {
      "name": "Y. Yang"
    },
    {
      "name": "A. Risukhina"
    },
    {
      "name": "A. Callear"
    },
    {
      "name": "C. Juntila-Raymond"
    },
    {
      "name": "E. Johnson"
    },
    {
      "name": "E.-T. Godonou"
    },
    {
      "name": "M. Smith"
    },
    {
      "name": "C. M. Midgley"
    },
    {
      "name": "J. M. Jones"
    },
    {
      "name": "A. S. Monto"
    },
    {
      "affs": [
        0
      ],
      "name": "E. T. Martin"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/63skfh9q3469e.bib",
  "cited_by": 0,
  "doi": "10.64898/2026.09.17.26363304",
  "fulltext_url": "https://www.medrxiv.org/content/10.64898/2026.09.17.26363304v1.full",
  "id": "63skfh9q3469e",
  "issns": [],
  "landing_url": "https://www.medrxiv.org/content/10.64898/2026.09.17.26363304v1",
  "language": null,
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "medrxiv",
      "epidemiology"
    ],
    [
      "openalex",
      "2725|SARS-CoV-2 and COVID-19 Research"
    ]
  ],
  "openalex": "W7213781476",
  "pdf_url": "https://www.medrxiv.org/content/10.64898/2026.09.17.26363304v1.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-09-17",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/63skfh9q3469e.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:18:56Z",
      "native_id": "10.64898/2026.09.17.26363304",
      "source": "medrxiv",
      "url": "https://www.medrxiv.org/content/10.64898/2026.09.17.26363304v1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "medrxiv:epidemiology",
      "subfield": "epidemiology-public-health"
    }
  ],
  "title": "Antibody boosting and short-term durability following SARS-CoV-2 infections in United States longitudinal cohorts, 2020-2024",
  "title_text": "Antibody boosting and short-term durability following SARS-CoV-2 infections in United States longitudinal cohorts, 2020-2024",
  "type": "preprint",
  "updated_at": "2026-10-30T12:18:56Z",
  "url": "https://research.draconitic.com/paper/63skfh9q3469e",
  "venue": "medRxiv",
  "versions": []
}